Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives

References

• Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005;8(11):1445–1449.
   PubMed Web of Science ®Google Scholar
• Petrakis IL. A rational approach to the pharmacotherapy of alcohol dependence. J Clinical Psychopharmacol. 2006;26(Suppl 1):S3–12.
   Google Scholar
• Salamone JD, Correa M, Mingote S, et al. Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J Pharmacol Exp Ther. 2003;305(1):1–8.
   PubMed Web of Science ®Google Scholar
• Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993;18(3):247–291.
   PubMed Web of Science ®Google Scholar
• Robinson TE, Berridge KC. The incentive sensitization theory of addiction: some current issues. Philos Trans R Soc Lond B Biol Sci. 2008;363(1507):3137–3146. doi:10.1098/rstb.2008.0093.
   PubMed Web of Science ®Google Scholar
• Schultz W, Tremblay L, Hollerman JR. Reward prediction in primate basal ganglia and frontal cortex. Neuropharmacology. 1998;37(4–5):421–429.
   PubMed Web of Science ®Google Scholar
• Berridge KC, Kringelbach ML. Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology (Berl). 2008;199(3):457–480.
   PubMed Web of Science ®Google Scholar
• Salamone JD, Cousins MS, Bucher S. Anhedonia or anergia? Effects of haloperidol and nucleus accumbens dopamine depletion on instrumental response selection in a T-maze cost/benefit procedure. Behav Brain Res. 1994;65(2):221–229.
   PubMed Web of Science ®Google Scholar
• Salamone JD, Correa M, Mingote SM, et al. Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr Opin Pharmacol. 2005;5(1):34–41.
   PubMed Web of Science ®Google Scholar
• Verheul R, Vanden Brink W, Geerlings P. A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol. 1999;34(2):197–222.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Leggio L, Abenavoli L, et al. Neurobiochemical and clinical aspects of craving in alcohol addiction: a review. Addict Behav. 2005;30(6):1209–1224.
   PubMed Web of Science ®Google Scholar
• Cox WM. “Alcohol alternatives: a goal for psychopharmacology?” By David J. Nutt. Journal of Psychopharmacol. 2006;20(3):327–328. discussion 31
   PubMed Web of Science ®Google Scholar
• Kishi T, Sevy S, Chekuri R, et al. Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. J Clin Psychiatry. 2013;74(7):e642–54.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Andreoli S, Di Nicola M, et al. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol. 2008;23(5):417–424. doi:10.1002/hup.944.
   PubMed Web of Science ®Google Scholar
• Hutchison KE, Ray L, Sandman E, et al. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006;31(6):1310–1317.
   PubMed Web of Science ®Google Scholar
• Walter H, Ramskogler K, Semler B, et al. Dopamine and alcohol relapse: D1 and D2 antagonists increase relapse rates in animal studies and in clinical trials. J Biomed Sci. 2001;8(1):83–88.
   PubMed Web of Science ®Google Scholar
• Wang J, Cheng Y, Wang X, et al. Alcohol elicits functional and structural plasticity selectively in dopamine D1 receptor-expressing neurons of the dorsomedial striatum. J Neurosci. 2015;35(33):11634–11643.
   PubMed Web of Science ®Google Scholar
• Martinez D, Gil R, Slifstein M, et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry. 2005;58(10):779–786.
   PubMed Web of Science ®Google Scholar
• Heinz A, Siessmeier T, Wrase J, et al. Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry. 2005;162(8):1515–1520.
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry. 2001;158(3):360–369.
   PubMed Web of Science ®Google Scholar
• Shapiro DS. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropharmacology. 2003;28:1400–1411.
   Google Scholar
• Keck PE Jr., McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs. 2003;12(4):655–662.
   PubMed Web of Science ®Google Scholar
• De Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs. 2015;29:773–799.
   PubMed Web of Science ®Google Scholar
• Hamamura T, Harada T. Unique pharmacological profile of aripiprazole as the phasic component buster. Psychopharmacology (Berl). 2007;191:741–743.
   PubMed Web of Science ®Google Scholar
• Ingman K, Kupila J, Hyytia P, et al. Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol Alcohol. 2006;41:391–398.
   PubMed Web of Science ®Google Scholar
• Jerlhag E. The antipsychotic aripiprazole antagonizes the ethanol- and amphetamine-induced locomotor stimulation in mice. Alcohol. 2008;42(2):123–127. doi:10.1016/j.alcohol.2007.11.004.
   PubMed Web of Science ®Google Scholar
• Shibasaki M, Kurokawa K, Mizuno K, et al. Effect of aripiprazole on anxiety associated with ethanol physical dependence and on ethanol-induced place preference. J Pharmacol Sci. 2012;118(2):215–224.
   PubMed Web of Science ®Google Scholar
• Nirogi R, Kandikere V, Jayarajan P, et al. Aripiprazole in an animal model of chronic alcohol consumption and dopamine D₂ receptor occupancy in rats. Am J Drug Alcohol Abuse. 2013;39(2):72–79. doi:10.3109/00952990.2012.730590.
   PubMed Web of Science ®Google Scholar
• Vergne DE, Anton RF. Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence. CNS Neurol Disord Drug Targets. 2010;9(1):50–54.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical Research Ed). 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• Janiri L, Martinotti G, Di Nicola M. Aripiprazole for relapse prevention and craving in alcohol-dependent subjects: results from a pilot study. J Clin Psychopharmacol. 2007;27(5):519–520.
   PubMed Web of Science ®Google Scholar
• Kenna GA, Leggio L, Swift RM. A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol. Hum Psychopharmacol. 2009;24(6):465–472. doi:10.1002/hup.1042.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Janiri L. Efficacy and safety of aripiprazole in alcohol dependence. Am J Drug Alcohol Abuse. 2007;33(3):393–401.
   PubMed Web of Science ®Google Scholar
• Han DH, Kim SM, Choi JE, et al. Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence. J Psychopharmacol. 2013;27(3):282–291. doi:10.1177/0269881112472563.
   PubMed Web of Science ®Google Scholar
• Anton RF, Kranzler H, Breder C, et al. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008;28(1):5–12. doi:10.1097/jcp.0b013e3181602fd4.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Di Giannantonio M, et al. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. J Psychopharmacol. 2009;23(2):123–129. doi:10.1177/0269881108089596.
   PubMed Web of Science ®Google Scholar
• Voronin K, Randall P, Myrick H, et al. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm—possible influence of self-control. Alcohol Clin Exp Res. 2008;32(11):1954–1961. doi:10.1111/j.1530-0277.2008.00783.x.
   PubMed Web of Science ®Google Scholar
• Myrick H, Li X, Randall PK, et al. The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol. 2010;30(4):365–372. doi:10.1097/JCP.0b013e3181e75cff.
   PubMed Web of Science ®Google Scholar
• Franken IH, Booij J, van den Brink W. The role of dopamine in human addiction: from reward to motivated attention. Eur J Pharmacol. 2005;526:199–206.
   PubMed Web of Science ®Google Scholar
• Kiefer F, Mann K. New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence. Eur J Pharmacol. 2005;526:163–171.
   PubMed Web of Science ®Google Scholar
• Everitt BJ, Hutcheson DM, Ersche KD, et al. The orbital prefrontal cortex and drug addiction in laboratory animals and humans. Ann N Y Acad Sci. 2007;1121:576–597.
   PubMed Web of Science ®Google Scholar
• Hutchison KE. Alcohol dependence: neuroimaging and the development of translational phenotypes. Alcohol Clin Exp Res. 2008;32(7):1111–1112. doi:10.1111/j.1530-0277.2008.00691.x.
   PubMed Web of Science ®Google Scholar
• Perra S, Clements MA, Bernier BE, et al. In vivo ethanol experience increases D(2) autoinhibition in the ventral tegmental area. Neuropsychopharmacology. 2011;36(5):993–1002. doi:10.1038/npp.2010.237.
   PubMed Web of Science ®Google Scholar
• Koob GF, Kenneth Lloyd G, Mason BJ. Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov. 2009;8(6):500–515. doi:10.1038/nrd2828.
   PubMed Web of Science ®Google Scholar
• Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217–238. doi:10.1038/npp.2009.110. Erratum in: Neuropsychopharmacology 2010; 35(4):1051.
   PubMed Web of Science ®Google Scholar
• Hatzigiakoumis DS, Martinotti G, Giannantonio MD, et al. Anhedonia and substance dependence: clinical correlates and treatment options. Front Psychiatry. 2011;2:10. doi:10.3389/fpsyt.2011.00010.
   PubMedGoogle Scholar
• Martinotti G, Andreoli S, Reina D, et al. Acetyl-l-Carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):953–958.
   PubMed Web of Science ®Google Scholar
• Pettorruso M, De Risio L, Di Nicola M, et al. Allostasis as a conceptual framework linking bipolar disorder and addiction. Front Psychiatry. 2014;5:173.
   PubMedGoogle Scholar
• Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction. Nat Neurosci. 2005;8:1442–1444.
   PubMed Web of Science ®Google Scholar
• Baler RD, Volkow ND. Drug addiction: the neurobiology of disrupted self-control. Trends Mol Med. 2006;12:559–566.
   PubMed Web of Science ®Google Scholar
• Monnelly EP, Ciraulo DA, Knapp C, et al. Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24:532–535.
   PubMed Web of Science ®Google Scholar
• Warsi M, Sattar SP, Bhatia SC, et al. Aripiprazole reduces alcohol use. Can J Psychiatry. 2005;50:244.
   PubMed Web of Science ®Google Scholar
• Bono G, Balducci C, Richelmi P, et al. Dopamine partial receptor agonists reduce ethanol intake in the rat. Eur J Pharmacol. 1996;296(3):233–238.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Cunningham KA. Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Psychopharmacology (Berl). 1997;130(1):41–58.
   PubMed Web of Science ®Google Scholar
• Beresford TP, Clapp L, Martin B, et al. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol. 2005;25(4):363–366.
   PubMed Web of Science ®Google Scholar
• Brunetti M, Di Tizio L, Dezi S, et al. Aripiprazole, alcohol and substance abuse: a review. Eur Rev Med Pharmacol Sci. 2012;16(10):1346–1354.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Corazza O, Achab S, et al. Novel psychoactive substances and behavioral addictions. Biomed Res Int. 2014;2014:1–2. doi:10.1155/2014/534523.
   Web of Science ®Google Scholar
• Bersani FS, Corazza O, Albano G, et al. The “Eyeballing” technique: an emerging and alerting trend of alcohol misuse. Eur Rev Med Pharmacol Sci. 2015;19(12):2311–2317.
   PubMed Web of Science ®Google Scholar
• Kiefer F, Jiménez-Arriero MA, Klein O, et al. Cloninger’s typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone. Addict Biol. 2008;13(1):124–129.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Tedeschi D, et al., Craving Study Group. Craving Typology Questionnaire (CTQ): a scale for alcohol craving in normal controls and alcoholics. Compr Psychiatry. 2013;54(7):925–932.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(6):e1000097. doi:10.1371/journal.pmed1000097
   PubMed Web of Science ®Google Scholar